Skip to main content
OpenTrials
Completed

NCT Number: NCT03402126

Tachy Prediction Download Study

The purpose of the Medtronic Tachy Prediction Download (TPD) study is to collect data from an implantable cardiac defibrillator (ICD) device that will be used to identify markers for imminent onset of ventricular arrhythmias.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Princess Margaret Hospital, Hong Kong

Loading trial locations.

About this study

The TPD Study is a prospective, non-randomized, non-interventional, multi-site data collection clinical study to collect ICD longitudinal data that may be used to develop a VT/VF prediction algorithm. The study subjects will include patients currently implanted, or who will be implanted with a market-approved Medtronic Evera MRI® ICD.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is implanted or will be implanted, with an Evera MRI device with properly functioning Medtronic tachycardia lead placed in the right ventricle (with or without atrial lead) with remaining device longevity of 4 years or more for:
  • Secondary Prevention or,
  • Primary Prevention and has had a device treated VT/VF or a device recorded episode of sustained VT/VF
  • Subject is ≥ 18 years old
  • Subject has previously documented history of VT/VF
  • Subject must be willing and able to use Medtronic CareLink network monitoring system
  • Subject provides signed and dated authorization and/or consent per institution and local requirements
  • Subject is willing and able to comply with the protocol

Exclusion criteria

  • Subject who received device for Primary Prevention indication and who has not had either a device treated VT/VF episode or a device recorded episode of sustained VT/VF
  • Subject is enrolled in a concurrent study that may confound the results of this study, without documented pre-approval from a Medtronic study manager
  • Subject has chronic AF
  • Subject has inherited disorders of ion transport mechanisms that predispose the subject to sudden death ("Channelopathies"): Long QT and Brugada Syndromes
  • Subject with multiple implanted active devices that may cause an interruption of a transmission of device data to CareLink
  • Subject has active electronic medical device other than an ICD
  • Subject requires more than 25% atrial or ventricular pacing
  • Subject has medical conditions that would limit study participation (per investigator judgment)
  • Subject has projected life expectancy of less than 1 year
  • Subject is pregnant or plans to be pregnant over the next year (females of child-bearing potential must have a negative pregnancy test within one week of enrollment and must practice a reliable form of birth control while enrolled in the study)
  • Subject meets exclusion criteria required by local law (e.g. age, breastfeeding, etc.)

Treatment and study plan

TPD RAMWare

Other

TPD RAMWare injected into enrolled subject's Implantable cardioverter-defibrillator (ICD) device for use

Primary outcomes

  1. Number of Participants With Device Detected Ventricular Tachycardia/Ventricular Fibrillation Episodes

    Time frame: 1 year

    This was a data collection study collecting data when implanted device detected Ventricular Tachycardia/Ventricular Fibrillation.

Sponsors and collaborators

Lead sponsor

Medtronic Cardiac Rhythm and Heart Failure

Industry

Registry information

Acronym: TPD

Important dates

Study start
2018
Primary completion
2020
Study completion
2020
First posted
Jan 18, 2018
Registry last updated
Nov 16, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.